Pathology: Understanding Your Report
At a Glance
An ovarian cystadenofibroma pathology report confirms whether the tumor is benign by examining its cyst lining and fibrous tissue, identifying the subtype, and checking thoroughly for borderline changes or cancerous invasion.
While imaging provides the first clues, the only way to definitively confirm a cystadenofibroma is through pathology. This process involves a specialized doctor, called a pathologist, examining the tumor tissue under a microscope after it has been surgically removed [1][2].
The Two Building Blocks
A cystadenofibroma is known as a biphasic tumor because it is made of two distinct parts that the pathologist must identify together [2]:
- Epithelial Component: This is the lining of the cysts. It can be made of different types of cells, which determines the tumor’s “subtype” [3].
- Stromal Component: This is a dense, fibrous tissue that makes up the solid parts of the tumor. In a cystadenofibroma, this fibrous tissue is a prominent feature [4][3].
Understanding the Subtypes
Pathologists classify your tumor based on the type of cells found in the epithelial lining:
- Serous: The most common subtype, often containing thin, watery fluid. These are sometimes found on both ovaries [5][3].
- Mucinous: These contain a thicker mucus. They frequently have multiple internal compartments (multilocular) [6][7].
- Mixed: These contain a combination of different cell types, such as both serous and mucinous elements [5].
Why “Extensive Sampling” is Critical
Because ovarian masses can be quite large and have complex internal structures, pathologists perform extensive sampling. They take multiple thin slices from representative areas of the tumor [8][9].
This thoroughness is necessary because these tumors can be heterogeneous, meaning one part might look perfectly benign while another small area could contain more concerning cells [10]. The sampling protocol varies depending on the tumor’s size, subtype, and how it looks to the naked eye. The pathologist’s goal is to ensure that no borderline (low-malignancy-potential) or malignant (cancerous) cells are hiding in the mass [4][9].
Distinguishing Benign from Borderline
The main challenge for a pathologist is telling the difference between a benign cystadenofibroma, a borderline tumor, and cancer.
- Benign (Cystadenofibroma): The epithelial cells are generally well-behaved, and the solid areas are confirmed to be harmless fibrous stroma [2].
- Borderline Tumor: The cells show increased proliferation, structural changes (like excessive “tufting” or “piling up”), and cellular atypia, but they do not aggressively invade the surrounding tissue [11][12].
- Malignant (Cancer): The cells show aggressive features and actively invade the surrounding fibrous tissue (stromal invasion) [12].
What a Final Report Means
If your final, permanent pathology report confirms a cystadenofibroma, it means the pathologist has reviewed the samples and found no evidence of borderline changes or malignant invasion [11]. This diagnosis is definitively benign. While the journey to this result often involves significant stress due to the tumor’s initial appearance on scans, the pathology report is the “gold standard” that provides the final answer [1][13].
Common questions in this guide
What does a benign cystadenofibroma result mean?
Why does the report describe the cyst lining and fibrous tissue?
Which cystadenofibroma subtypes might appear on my report?
Why was my ovarian mass examined in many different places?
How can pathology distinguish cystadenofibroma from cancer?
Get notified when new evidence is published on cystadenofibroma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
A Rare Case of Bilateral Serous Cystadenofibroma in a Malignant Disguise.
Ansari SA, AlSindi K, Aldoseri F
The Gulf journal of oncology 2022; (1(40)):67-70.
PMID: 36448072 - 2
Serous ovarian cystadenofibroma and review of the literature: Report of a case.
Bencherifi Y, Watik F, Lyafi Y, et al.
International journal of surgery case reports 2023; (110()):108649 doi:10.1016/j.ijscr.2023.108649.
PMID: 37639968 - 3
Diagnosis and treatment of a serous cystadenofibroma-like tumor potentially arising from urinary tract endometriosis: A case report.
Horibe Y, Takase R, Kanno T, et al.
Taiwanese journal of obstetrics & gynecology 2025; (64(2)):357-360 doi:10.1016/j.tjog.2024.12.014.
PMID: 40049826 - 4
Borderline serous ovarian neoplasm: case report of a diagnostic challenge in intraoperative frozen sections.
Rana F, Mishra M, Saha K, Narayan R
Case reports in women's health 2020; (27()):e00219 doi:10.1016/j.crwh.2020.e00219.
PMID: 32461918 - 5
Ovarian Cystadenofibroma: An Overview.
V V, Samal S
Cureus 2025; (17(7)):e87614 doi:10.7759/cureus.87614.
PMID: 40786313 - 6
Müllerian Mucinous Cystadenomas of the Ovary: A Report of 25 Cases of an Unheralded Benign Ovarian Neoplasm Often Associated With Endometriosis and a Brief Consideration of Neoplasms Arising From the Latter.
Watkins JC, Young RH
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2022; (41(1)):68-75 doi:10.1097/PGP.0000000000000765.
PMID: 33577227 - 7
Endocrine cell micronests in an ovarian mucinous borderline tumor: a potential diagnostic pitfall for microinvasion.
Collins K, Segura S, Hwang M
Diagnostic pathology 2022; (17(1)):37 doi:10.1186/s13000-022-01217-4.
PMID: 35422044 - 8
Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls.
Buza N
Archives of pathology & laboratory medicine 2019; (143(1)):47-64 doi:10.5858/arpa.2018-0289-RA.
PMID: 30785337 - 9
Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors.
Dewilde K, Moerman P, Leunen K, et al.
Gynecologic and obstetric investigation 2018; (83(1)):65-69 doi:10.1159/000478929.
PMID: 28689208 - 10
Accuracy of frozen section diagnosis and factors associated with final pathological diagnosis upgrade of mucinous ovarian tumors.
Park JY, Lee SH, Kim KR, et al.
Journal of gynecologic oncology 2019; (30(6)):e95 doi:10.3802/jgo.2019.30.e95.
PMID: 31576689 - 11
MRI of Borderline Epithelial Ovarian Tumors: Pathologic Correlation and Diagnostic Challenges.
Tsuboyama T, Sato K, Ota T, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(7)):2095-2111 doi:10.1148/rg.220068.
PMID: 36083804 - 12
Ovarian serous borderline tumors with noninvasive and invasive peritoneal implants: A case report each.
Srinivasamurthy BC, Kulandai Velu AR, Krishnan N, Patil AS
Journal of cancer research and therapeutics 2015; (11(3)):646 doi:10.4103/0973-1482.147707.
PMID: 26458602 - 13
Ovarian remnant syndrome with paraintestinal ovarian serous cystadenofibroma arose 30 years after bilateral salpingo-oophorectomy: A case report.
Tien CT, Cheng CH, Ding DC
Medicine 2022; (101(44)):e31205 doi:10.1097/MD.0000000000031205.
PMID: 36343074
This page is for informational purposes only and does not constitute medical advice. Your pathologist and treating clinician should interpret your individual report and advise about follow-up.